190 related articles for article (PubMed ID: 32162095)
41. Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells.
Ricciardelli I; Blundell MP; Brewin J; Thrasher A; Pule M; Amrolia PJ
Blood; 2014 Oct; 124(16):2514-22. PubMed ID: 25185261
[TBL] [Abstract][Full Text] [Related]
42. Epstein-Barr virus (EBV)-associated post-transplantation lymphoproliferative disorder simultaneously affecting both B and T cells after allogeneic bone marrow transplantation.
Chuhjo T; Yachie A; Kanegane H; Kimura H; Shiobara S; Nakao S
Am J Hematol; 2003 Apr; 72(4):255-8. PubMed ID: 12666136
[TBL] [Abstract][Full Text] [Related]
43. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy.
Sherritt MA; Bharadwaj M; Burrows JM; Morrison LE; Elliott SL; Davis JE; Kear LM; Slaughter RE; Bell SC; Galbraith AJ; Khanna R; Moss DJ
Transplantation; 2003 May; 75(9):1556-60. PubMed ID: 12792514
[TBL] [Abstract][Full Text] [Related]
44. [Adoptive immune therapy using EBV-specific CTL].
Kuzushima K; Morishima T
Nihon Rinsho; 1997 Feb; 55(2):473-8. PubMed ID: 9046843
[TBL] [Abstract][Full Text] [Related]
45. Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities.
Al Hamed R; Bazarbachi AH; Mohty M
Bone Marrow Transplant; 2020 Jan; 55(1):25-39. PubMed ID: 31089285
[TBL] [Abstract][Full Text] [Related]
46. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients.
Savoldo B; Goss J; Liu Z; Huls MH; Doster S; Gee AP; Brenner MK; Heslop HE; Rooney CM
Transplantation; 2001 Sep; 72(6):1078-86. PubMed ID: 11579304
[TBL] [Abstract][Full Text] [Related]
47. Cytotoxic T-lymphocyte therapy for post-transplant lymphoproliferative disorder after solid organ transplantation in children.
Chiou FK; Beath SV; Wilkie GM; Vickers MA; Morland B; Gupte GL
Pediatr Transplant; 2018 Mar; 22(2):. PubMed ID: 29388302
[TBL] [Abstract][Full Text] [Related]
48. Epstein-Barr virus-associated posttransplant lymphoproliferative disorders: new insights in pathogenesis, classification and treatment.
Dierickx D; Pociupany M; Natkunam Y
Curr Opin Oncol; 2022 Sep; 34(5):413-421. PubMed ID: 35900750
[TBL] [Abstract][Full Text] [Related]
49. Epstein-Barr virus, B cell lymphoproliferative disease, and SCID mice: modeling T cell immunotherapy in vivo.
Johannessen I; Bieleski L; Urquhart G; Watson SL; Wingate P; Haque T; Crawford DH
J Med Virol; 2011 Sep; 83(9):1585-96. PubMed ID: 21739450
[TBL] [Abstract][Full Text] [Related]
50. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells.
Moosmann A; Bigalke I; Tischer J; Schirrmann L; Kasten J; Tippmer S; Leeping M; Prevalsek D; Jaeger G; Ledderose G; Mautner J; Hammerschmidt W; Schendel DJ; Kolb HJ
Blood; 2010 Apr; 115(14):2960-70. PubMed ID: 20103780
[TBL] [Abstract][Full Text] [Related]
51. Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients.
Barker JN; Martin PL; Coad JE; DeFor T; Trigg ME; Kurtzberg J; Weisdorf DJ; Wagner J
Biol Blood Marrow Transplant; 2001; 7(7):395-9. PubMed ID: 11529490
[TBL] [Abstract][Full Text] [Related]
52. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
Mentzer SJ; Perrine SP; Faller DV
Transpl Infect Dis; 2001 Sep; 3(3):177-85. PubMed ID: 11493400
[TBL] [Abstract][Full Text] [Related]
53. Immunotherapy for Epstein-Barr virus-associated cancers in children.
Straathof KC; Bollard CM; Rooney CM; Heslop HE
Oncologist; 2003; 8(1):83-98. PubMed ID: 12604735
[TBL] [Abstract][Full Text] [Related]
54. Adoptive cellular immunotherapy for EBV lymphoproliferative disease.
Heslop HE; Rooney CM
Immunol Rev; 1997 Jun; 157():217-22. PubMed ID: 9255632
[TBL] [Abstract][Full Text] [Related]
55. EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas.
McLaughlin LP; Gottschalk S; Rooney CM; Bollard CM
Methods Mol Biol; 2017; 1532():255-265. PubMed ID: 27873282
[TBL] [Abstract][Full Text] [Related]
56. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
Khanna R; Burrows SR; Nicholls J; Poulsen LM
Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
[TBL] [Abstract][Full Text] [Related]
57. Epstein-Barr virus-related lymphoproliferative disorders in T-cell repleted haploidentical transplantation with post-transplant cyclophosphamide.
Uygun V; Özsan N; Daloğlu H; Öztürkmen S; Yalçın K; Karasu G; Yeşilipek A
Int J Hematol; 2022 Apr; 115(4):600-604. PubMed ID: 34826107
[TBL] [Abstract][Full Text] [Related]
58. Immune reconstitution of HLA-A*0201/BMLF1- and HLA-A*1101/LMP2-specific Epstein Barr virus cytotoxic T lymphocytes within 90 days after haploidentical hematopoietic stem cell transplantation.
Zhou L; Lu DP
Virol J; 2019 Feb; 16(1):19. PubMed ID: 30736814
[TBL] [Abstract][Full Text] [Related]
59. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.
Lim WH; Russ GR; Coates PT
Nephrology (Carlton); 2006 Aug; 11(4):355-66. PubMed ID: 16889577
[TBL] [Abstract][Full Text] [Related]
60. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients.
Nalesnik MA; Rao AS; Furukawa H; Pham S; Zeevi A; Fung JJ; Klein G; Gritsch HA; Elder E; Whiteside TL; Starzl TE
Transplantation; 1997 May; 63(9):1200-5. PubMed ID: 9158009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
